Evaluation of viral load and anticoenemia as markers for relapse cytomegalovirus infection in renal transplant recipients;Estudio de carga viral y antigenemia como valores predictivos de recidiva de infección CMV en el trasplante renal

Nefrologia

Volumn 27, Issue 2, 2007, Pages 202-208

  Franco, Antonio ^a   Serrano, R ^a   Gimeno, A ^a   De Juan, J ^a   Merino, E ^a   Jimenez Del Cerro L ^a   Olivares, J ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

CMV infection; Relapse; Renal transplantation; Viral load

Indexed keywords

BIOLOGICAL MARKER; VIRUS ANTIGEN;

ARTICLE; BLOOD; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; FEMALE; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RECURRENT DISEASE; VIROLOGY; VIRUS LOAD;

ANTIGENS, VIRAL; BIOLOGICAL MARKERS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; VIRAL LOAD;

EID: 34548381266     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Rubin RH: Infectious disease complications of renal transplantation. Kidney Int 44 (1): 221-236, 1993.
2. Brennan DC: Cytomegalovirus in Renal Transplantation. J Am Soc Nephrol 12: 848-855, 2001.
3. Smith SR, Butterly DW, Alexander BD, Greenberg A: Viral infections after renal transplantation. Am J Kidney Dis 37: 659-676, 2001.
4. Rubin RH: The indirect effects of cytomegalovirus infection on the outcome of organ trasplantation. J Am Med Assoc 261: 3607-3609,1989.
5. Pouteil-Noble C, Ecochard R, Landrivon G y cols.: Cytomegalovirus infection an etiological factor for rejection? A prospective study in 242 renal transplant recipients. Transplantation 55: 851-857, 1993.
6. Matas AJ, Gillingham KJ, Payne WD, Najarian JS: The impact of an acute rejection episode on long-term renal allograft survival. Transplantation 57: 857-59, 1994.
7. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV: Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 181 (2): 717-720, 2000.
8. Humar A, Kumar D, Boivin G, Caliendo AM: Cytomegalovirus (CMV) virus load kinectics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 186: 829-833, 2002.
9. Falages ME, Snydman DR, Griffith J, Werner BG, Freeman R, Rohrer R: Clinical and epidermiological predictor of recurrent cytomegalovirus disease on orthotopic liver transplant recipients. Boston Center for Liver Transplantation. CMV Ig study group. Clin Infect Dis 25: 314-317, 1997.
10. Van den berg AP, Van Son WS, Haagsma EB, Schirm J, Diskstra G, Van der Giessen M, Slooff MJM: The TH. Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid organ transplant recipients. Transplantation 55: 847-851, 1993.
11. Imbert-Marcille BM, Cantarovich D, Ferre-Aubineau V, Richet B, Soulillou JP, Billaudel S: Usefullness of DNA viral loa quantification for cytomegalovirus disease monitoring in renal and pancreas/renal transplant recipients. Transplantation 63: 1476-1481, 1997.
12. Robers TC, Brennan DC, Buller RS, Gaudreault-Keener, Schnitzler MA, Sternhell KE, Garlock KA, Singer GG, Storch GA: Quantitative polymerase chain reaction to predict occurrence of symtomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients. J Infect Dis 178: 626-635, 1998.
13. Pérez JL, Salva J, Niubo J: La prueba de antigenemia para citomegalovirus. Enferm Infecc Mycrobiol Clin 12: 252-269, 1994.
14. Balfour HH, Chace BA, Stapleton JT, Simmons RL, Fryd DS: A randomized placebo-controlled trial of oral aciclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 330: 1381-1387, 1989.
15. Goral S, Ynares C, Dummer S, Helderman JH: Aciclovir prophylaxis for cytomegalovirus disease in high risk renal transplant recipients: is it effective? Kidney Int (Supl. 57): 62-65, 1996.
16. Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP. Tilney NL, Kirlman RL, Milford EL, Cho SI, Bush HL Jr, Levey AS: Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipient. N Engl J Med 317: 1049-1054, 1987.
17. Payá C, Humar A, Domínguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD: Eficacia y seguridad de Valganciclovir frente a ganciclovir oral para la prevención de la enfermedad por citomegalovirus en receptores de trasplante de órgano sólido. Am J Transplant 4: 611-620, 2004.
18. Nutley NJ: Cytovene (Ganciclovir) package insert. Roche Laboratories; 2000.
19. Greenberg RN: Overview of patient compliance with medication dosing: a literature review. Clin Ther 6: 592-599, 1984.
20. Claxton AJ, Cramer J, Pierce C: A systematic review of the association between dose regimens and medication compliance. Clin Ther 23: 1296-1300, 2001.
21. Geddes CC, Church CC, Collidge T, McCruden E, Gillespie J, Matthews E, Hainmueller A, Briggs JD: Management of cytomegalovirus infection by weekly surveillance alter renal transplant: analisys of cost, rejection and renal function. Nephrol Dial Transplant 18: 1891-1898, 2003.
22. Humar A, Uknis M, Carlone-Jambor C, Gruessner RW, Dunn DL, Matas A: Citomegalovirus disease recurrente after ganciclovir treatment in kidney and kidney- pancreas transplant recipients. Transplantation 67: 94-97, 1999.